Higher doses tested for Tough-to-Treat arthritis
NCT ID NCT00691028
Summary
This study tested whether giving higher doses of the drug infliximab (TA-650) could better control rheumatoid arthritis in patients who were still experiencing symptoms despite taking methotrexate. Over 300 participants received one of three different maintenance doses after initial treatment. The main goal was to see if the higher doses were more effective at reducing joint pain, swelling, and disease activity over 54 weeks, and to monitor safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.